Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TELECAST: Telotristat Etiprate in Carcinoid Syndrome
NCT02063659Phase 3Completed
- Sponsor
- Lexicon Pharmaceuticals, Inc.
- Start
- Mar 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 11
01
Overview
Phase 3, randomised, double-blind trial of telotristat ethyl in Carcinoid Syndrome (CS) (3 arms), sponsored by Lexicon Pharmaceuticals, Inc. Primary endpoints: Treatment-Emergent Adverse Events at 17.1 weeks, Urinary 5-hydroxyindoleacetic Acid at 12 weeks and 1 more. Started Mar 2014; status: completed.
02
Drugs
telotristat ethyl
03
Conditions
Carcinoid Syndrome (CS)
Beyond the preview
Go deeper on NCT02063659.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02063659.